康方生物-B(09926.HK):新型腫瘤免疫治療藥物AK112啟動多項臨牀研究
格隆匯5月12日丨康方生物-B(09926.HK)發佈公吿,公司自主研發的新型腫瘤免疫治療藥物PD-1/VEGF雙特異性抗體(研發代號:AK112),在中國、澳大利亞等國家開展了劑量爬坡和擴展的I期臨牀研究後,再分別開展多項單藥或聯合用藥的臨牀研究。
根據披露,這是繼全球首創的Cadonilimab(PD-1/CTLA-4雙特異性抗體)在中國和美國同時推進註冊性II期臨牀試驗後,公司又一個率先進入後期臨牀階段的全球首創雙特異性抗體藥物。
AK112同時具有免疫治療藥物和抗血管生成藥物的療效特性。在早期臨牀研究獲得良好結果的基礎上,AK112的多個項目同時而快速地進一步進入概念驗證性(POC)的臨牀研究階段。憑藉高效的臨牀運營能力,公司期待在未來12個月內獲得更多AK112在相關適應症上的研究成果。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.